[go: up one dir, main page]

EA199900467A3 - Составы на основе зипразидона - Google Patents

Составы на основе зипразидона

Info

Publication number
EA199900467A3
EA199900467A3 EA199900467A EA199900467A EA199900467A3 EA 199900467 A3 EA199900467 A3 EA 199900467A3 EA 199900467 A EA199900467 A EA 199900467A EA 199900467 A EA199900467 A EA 199900467A EA 199900467 A3 EA199900467 A3 EA 199900467A3
Authority
EA
Eurasian Patent Office
Prior art keywords
ziprasidone
formulations
ziprasidone formulations
Prior art date
Application number
EA199900467A
Other languages
English (en)
Other versions
EA002223B1 (ru
EA199900467A2 (ru
Inventor
Фрэнк Роберт Буш
Энджела Кэрол Гэтлин Хосбергер
Байджен Расейди
Даниэл Рей Аренсон
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199900467(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA199900467A2 publication Critical patent/EA199900467A2/ru
Publication of EA199900467A3 publication Critical patent/EA199900467A3/ru
Publication of EA002223B1 publication Critical patent/EA002223B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyamides (AREA)
  • Detergent Compositions (AREA)
  • Feeding Of Articles By Means Other Than Belts Or Rollers (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EA199900467A 1998-06-15 1999-06-15 Составы на основе зипразидона EA002223B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8922998P 1998-06-15 1998-06-15

Publications (3)

Publication Number Publication Date
EA199900467A2 EA199900467A2 (ru) 1999-12-29
EA199900467A3 true EA199900467A3 (ru) 2000-04-24
EA002223B1 EA002223B1 (ru) 2002-02-28

Family

ID=22216447

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900467A EA002223B1 (ru) 1998-06-15 1999-06-15 Составы на основе зипразидона

Country Status (44)

Country Link
US (1) US6150366A (ru)
EP (1) EP0965343B1 (ru)
JP (2) JP3441676B2 (ru)
KR (1) KR100338915B1 (ru)
CN (1) CN1307994C (ru)
AP (1) AP1216A (ru)
AR (1) AR015553A1 (ru)
AT (1) ATE240732T1 (ru)
AU (1) AU753820B2 (ru)
BG (1) BG64691B1 (ru)
BR (1) BR9902268A (ru)
CA (1) CA2274338C (ru)
CO (1) CO5070579A1 (ru)
CY (1) CY2003002I1 (ru)
CZ (1) CZ297954B6 (ru)
DE (1) DE69908021T2 (ru)
DK (1) DK0965343T3 (ru)
EA (1) EA002223B1 (ru)
ES (1) ES2197581T3 (ru)
GT (1) GT199900080A (ru)
HN (1) HN1999000089A (ru)
HR (1) HRP990193B1 (ru)
HU (1) HU226487B1 (ru)
ID (1) ID23546A (ru)
IL (1) IL130424A (ru)
IS (1) IS2182B (ru)
MA (1) MA26647A1 (ru)
MY (1) MY121397A (ru)
NO (1) NO316713B1 (ru)
NZ (1) NZ336271A (ru)
OA (1) OA11064A (ru)
PA (1) PA8475601A1 (ru)
PE (1) PE20000632A1 (ru)
PL (2) PL195606B1 (ru)
PT (1) PT965343E (ru)
RS (1) RS49611B (ru)
SG (1) SG77243A1 (ru)
SI (1) SI0965343T1 (ru)
SK (1) SK286245B6 (ru)
TR (1) TR199901379A2 (ru)
TW (1) TW590774B (ru)
UA (1) UA59383C2 (ru)
UY (1) UY25649A1 (ru)
ZA (1) ZA993938B (ru)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US7175855B1 (en) * 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
KR100477782B1 (ko) * 1999-05-27 2005-03-21 화이자 프로덕츠 인코포레이티드 지프라시돈 현탁액
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2932964A1 (en) 2000-10-30 2015-10-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
WO2003097046A1 (en) * 2002-05-17 2003-11-27 Duke University Method for treating obesity
US7488729B2 (en) * 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
WO2004089948A1 (en) * 2003-04-11 2004-10-21 Hetero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
DE602004012403T2 (de) * 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
WO2005016325A2 (en) * 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
CN1874761A (zh) * 2003-09-02 2006-12-06 辉瑞产品公司 齐拉西酮的持续释放剂型
WO2005040160A2 (en) * 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
EP1687300A4 (en) * 2003-11-28 2007-08-01 Wockhardt Ltd PROCESS FOR THE PREPARATION OF ZIPRASIDONE MONOHYDROCHLORIDE HYDRATE
WO2005061493A2 (en) 2003-12-18 2005-07-07 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
BRPI0506829A (pt) * 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005085240A2 (en) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Process for the preparation of ziprasidone
US20050277579A1 (en) * 2004-05-03 2005-12-15 Ranga Krishnan Compositions for affecting weight loss
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
WO2006026426A2 (en) * 2004-08-27 2006-03-09 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer’s disease peripherally
US20090142404A1 (en) 2004-08-31 2009-06-04 Pfizer Inc Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
US20080268034A1 (en) * 2005-01-07 2008-10-30 Girish Karanth Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
US20070032511A1 (en) * 2005-02-11 2007-02-08 Judith Aronhime Amorphous ziprasidone mesylate
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
RU2407529C2 (ru) * 2005-04-13 2010-12-27 Пфайзер Продактс Инк. Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц
JP2008538582A (ja) * 2005-04-22 2008-10-30 ワイス 精神病性障害の治療または予防のための新規の治療的組み合わせ
SI1884242T1 (sl) 2005-05-26 2013-07-31 Dainippon Sumitomo Pharma Co., Ltd. Farmacevtski sestavek, ki vsebuje lurazidon
KR20080024206A (ko) * 2005-06-20 2008-03-17 엘란 파마 인터내셔널 리미티드 아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물
JP2008546781A (ja) * 2005-06-20 2008-12-25 エラン・ファルマ・インターナショナル・リミテッド アリール−複素環式化合物を含んでなるナノ粒状及び制御放出の組成物
PL2135603T3 (pl) 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
AR057946A1 (es) * 2005-11-28 2007-12-26 Orexigen Therapeutics Inc Formulacion de zonisamida de liberacion sostenidda
PL379569A1 (pl) * 2006-04-28 2007-10-29 Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1892243A1 (en) * 2006-08-02 2008-02-27 KRKA, tovarna zdravil, d.d., Novo mesto Polymorphic forms of ziprasidone sulphate salts
EP1889844A3 (en) * 2006-08-02 2008-03-05 Krka Polymorphic forms of ziprasidone sulphates
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
EP2089005B1 (en) 2006-11-09 2010-03-17 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
AU2008254957A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
WO2009032558A2 (en) * 2007-08-31 2009-03-12 Dr. Reddy's Laboratories Ltd. Preparation of ziprasidone hydrochloride monohydrate
US8410268B2 (en) * 2008-03-11 2013-04-02 Alkem Laboratories Limited Process for the preparation of ziprasidone
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
NZ597108A (en) 2009-06-25 2014-04-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds
EP2340834A1 (en) 2009-12-30 2011-07-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Enhanced Solubility of Ziprasidone
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
PL3251660T3 (pl) 2010-02-25 2020-02-28 Bristol-Myers Squibb Holdings Ireland Unlimited Company Formulacje apiksabanu
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
PT790236E (pt) * 1996-02-13 2004-04-30 Pfizer Pro-farmacos de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-di-hidro-2h-indol-2-ona
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit

Also Published As

Publication number Publication date
CA2274338C (en) 2003-04-15
AP1216A (en) 2003-10-19
DE69908021D1 (de) 2003-06-26
PL195209B1 (pl) 2007-08-31
YU27199A (sh) 2002-12-10
GT199900080A (es) 2000-11-29
MY121397A (en) 2006-01-28
EA002223B1 (ru) 2002-02-28
DE69908021T2 (de) 2003-11-27
IS5079A (is) 1999-12-16
IL130424A (en) 2003-10-31
HU226487B1 (en) 2009-03-02
UA59383C2 (ru) 2003-09-15
SK76999A3 (en) 2000-12-11
AP9901579A0 (en) 1999-06-30
CZ212799A3 (cs) 2000-09-13
CO5070579A1 (es) 2001-08-28
PL333737A1 (en) 1999-12-20
NO992892L (no) 1999-12-16
CA2274338A1 (en) 1999-12-15
BG64691B1 (bg) 2005-12-30
HU9901960D0 (en) 1999-08-30
EP0965343B1 (en) 2003-05-21
KR100338915B1 (ko) 2002-05-30
AR015553A1 (es) 2001-05-02
IL130424A0 (en) 2000-06-01
JP2000007566A (ja) 2000-01-11
HN1999000089A (es) 1999-11-03
EP0965343A3 (en) 2000-02-23
TW590774B (en) 2004-06-11
HRP990193B1 (en) 2003-08-31
ID23546A (id) 2000-05-04
CN1307994C (zh) 2007-04-04
BR9902268A (pt) 2000-05-02
SK286245B6 (sk) 2008-06-06
DK0965343T3 (da) 2003-08-04
NZ336271A (en) 2000-10-27
PL195606B1 (pl) 2007-10-31
ATE240732T1 (de) 2003-06-15
ES2197581T3 (es) 2004-01-01
PA8475601A1 (es) 2000-09-29
PE20000632A1 (es) 2000-07-26
NO316713B1 (no) 2004-04-13
UY25649A1 (es) 2000-02-23
BG103489A (en) 2000-07-31
IS2182B (is) 2006-12-15
HUP9901960A2 (hu) 2000-08-28
AU3398399A (en) 1999-12-23
OA11064A (en) 2002-03-13
CN1242987A (zh) 2000-02-02
RS49611B (sr) 2007-06-04
CZ297954B6 (cs) 2007-05-09
HK1024184A1 (en) 2000-10-05
JP2002003492A (ja) 2002-01-09
MA26647A1 (fr) 2004-12-20
US6150366A (en) 2000-11-21
AU753820B2 (en) 2002-10-31
JP3441676B2 (ja) 2003-09-02
SI0965343T1 (en) 2003-10-31
NO992892D0 (no) 1999-06-14
TR199901379A2 (xx) 2000-01-21
HRP990193A2 (en) 2000-02-29
CY2003002I1 (el) 2009-11-04
EA199900467A2 (ru) 1999-12-29
ZA993938B (en) 2000-12-14
PT965343E (pt) 2003-08-29
EP0965343A2 (en) 1999-12-22
JP4187423B2 (ja) 2008-11-26
KR20000006143A (ko) 2000-01-25
SG77243A1 (en) 2000-12-19
HUP9901960A3 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
SG77243A1 (en) Ziprasidone formulations
GB9804013D0 (en) Formulations
EP1113799A4 (en) PROTEIN-BASED PREPARATION
GB9715751D0 (en) Formulations
GB0014805D0 (en) Glassbreaker (2)
GB9806312D0 (en) Novel formulations
GB9815002D0 (en) Formulations
GB9815001D0 (en) Formulations
EP1148957A4 (en) GUIDE WIRE
GB9810181D0 (en) Novel formulations
GB9901323D0 (en) Freeface 1
EG24008A (en) Ziprasidone formulations
GB0028459D0 (en) Glor 2
GB9916299D0 (en) Dogex 1
GB9910118D0 (en) Formulations
GB9810143D0 (en) Parasiticidal formulations
GB9909080D0 (en) Novel formulations
GB9909079D0 (en) Novel formulations
GB9720228D0 (en) Parasiticidal formulations
GB9823645D0 (en) Formulation
SI1468689T1 (sl) Pripravek 2-metil-tieno-benzodiazepina
GB9703100D0 (en) Formulations
GB9703099D0 (en) Formulations
GB9703101D0 (en) Formulations
GB9704521D0 (en) Formulations

Legal Events

Date Code Title Description
ND4A Extension of term of a eurasian patent

Designated state(s): AM AZ BY KG MD TJ

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU